Analysts Rahman and McCarthy hold a conference call with CFO Zante on April 30 hosted by Maxim Group.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VKTX:
- Promising Developments and Strong Financial Position Bolster Buy Rating for Viking Therapeutics
- Viking Therapeutics: Promising Pipeline and Strategic Execution Drive Buy Rating
- Viking Therapeutics price target lowered to $85 from $96 at B. Riley
- Viking Therapeutics: Strong Financials and Promising VK2735 Program Drive Buy Rating
- Viking Therapeutics Advances Clinical Pipeline in Q1 2025